ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,139Medicare Part D Prescriptions Filled, Including Refills

Rank: 45 out of 198

$555K Total Retail Price of All Prescriptions

Rank: 47 out of 198

498 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
14% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 498 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

10% of this provider’s 498 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 10,354 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
AMLODIPINE BESYLATE 551 531 1 4
LEVOTHYROXINE SODIUM 463 431 2 1
OMEPRAZOLE 406 393 3 3
PRAVASTATIN SODIUM 384 362 4 19
LISINOPRIL 369 337 5 6
METOPROLOL SUCCINATE 368 362 6 11
SIMVASTATIN 327 310 7 2
ATORVASTATIN CALCIUM 212 194 8 12
HYDROCODONE-ACETAMINOPHEN 200 168 S3 9 8
METOPROLOL TARTRATE 198 198 10 10
METFORMIN HCL 193 179 11 13
TRAMADOL HCL 190 172 12 15
FUROSEMIDE 182 171 13 5
LOSARTAN POTASSIUM 176 171 14 18
WARFARIN SODIUM 171 168 15 7
GABAPENTIN 161 148 16 14
FLUTICASONE PROPIONATE 161 147 16 39
HYDROCHLOROTHIAZIDE 157 152 18 16
FENOFIBRATE 147 129 19 61
GLIMEPIRIDE 136 130 20 35
ZOLPIDEM TARTRATE 134 133 21 22
ALENDRONATE SODIUM 123 111 22 21
LOVASTATIN 115 110 23 70
CITALOPRAM HBR 113 106 24 20
DONEPEZIL HCL 111 111 25 28
MELOXICAM 110 110 26 30
ALLOPURINOL 105 105 27 23
TAMSULOSIN HCL 104 101 28 27
NAMENDA 97 97 29 33
BENAZEPRIL HCL 96 91 30 45
POTASSIUM CHLORIDE 96 89 30 9
PANTOPRAZOLE SODIUM 94 94 32 31
FINASTERIDE 93 87 33 94
LISINOPRIL-HYDROCHLOROTHIAZIDE 91 76 34 38
CLOPIDOGREL 86 84 35 42
ATENOLOL 82 82 36 17
MIRTAZAPINE 80 80 37 44
SERTRALINE HCL 79 79 38 25
SPIRONOLACTONE 73 73 39 37
NIASPAN 70 56 40 138
ZETIA 67 65 41 68
TRIAMTERENE-HCTZ 66 63 42 32
TRAZODONE HCL 65 65 43 50
DOXAZOSIN MESYLATE 62 62 44 96
CARVEDILOL 62 53 44 24
PLAVIX 58 54 46 66
SYNTHROID 57 57 47 36
AMOX TR-POTASSIUM CLAVULANATE 53 43 48 154
ROPINIROLE HCL 53 53 48 74
LANTUS SOLOSTAR 52 51 50 85
CRESTOR 51 48 51 26
TERAZOSIN HCL 51 51 51 102
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 3, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.